Lifeline Scientific (LSE:LSI) Momentum Rank : 0 (As of Jun. 05, 2024)

View and export this data going back to . Start your Free Trial

What is Lifeline Scientific Momentum Rank?

Lifeline Scientific has the Momentum Rank of 0.

For Momentum Rank, we considered the residual momentum concept that was widely studied by Blitz and his colleagues as well as by Nobel Prize laureates Fama and French. However, we did not find any significant differences in the performances of stocks with different ranks of residual momentum. Therefore, we use traditional momentum instead.

Momentum Rank is determined using the standardized momentum ratio and other momentum indicators. The standardized momentum ratio is the average of the performances from 12 months ago to 1 month ago and 6 months ago to 1 month ago, divided by the beta of the stock over the past 12 months. To calculate the momentum ratio today, we would use the average of the two performance numbers.

For momentum, we found that stock price performance does not have a monotonic correlation with the momentum ratio. The stocks with the highest momentum ratios perform worse than those at about the 70th percentile. Therefore, for the momentum rank, we ranked the stocks at about the 70th percentile of the momentum ratio as the highest at 10.

Please click GF Score to see more details on the GF Score's 5 Key Aspects of Analysis.

Lifeline Scientific Momentum Rank Related Terms

Thank you for viewing the detailed overview of Lifeline Scientific's Momentum Rank provided by GuruFocus.com. Please click on the following links to see related term pages.

Lifeline Scientific (LSE:LSI) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Lifeline Scientific Inc (LSE:LSI) » Definitions » Momentum Rank

Comparable Companies

Traded in Other Exchanges

N/A

Address

Website

http://www.lifeline-scientific.com

Lifeline Scientific Inc was incorporated on October 1, 1998. The Company is in the business of delivering, to targeted medical markets, a portfolio of related proprietary technologies, which include devices, solutions, and protocols designed to maximize the use and availability of organs, tissues, and cells. It serves the kidney transplant market today with its LifePort product line, and also sells solutions to service the broader organ transplant industry. The Company operates in North America, Brazil, China and Rest of World.